[Federal Register Volume 68, Number 231 (Tuesday, December 2, 2003)]
[Notices]
[Pages 67475-67476]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-29961]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on April 25,

[[Page 67476]]

2003, Lifepoint, Inc., 10400 Trademark Street, Rancho Cucamonga, 
California 91730, made application by renewal to the Drug Enforcement 
Administration (DEA) for registration as a bulk manufacturer of the 
basic classes of controlled substances listed below:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)...............  I
3,4-Methylenedioxyamphetamine (7400).......  I
3,4-Methylenedioxy-N-ethylamphetamine        I
 (7404).
3,4-Methylenedioxymethamphetamine (7405)...  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
phencyclidine (7471).......................  II
Benzoylecogonine (9180)....................  II
Morphine (9300)............................  II
------------------------------------------------------------------------

    The firm plans to produce small quantities of controlled substances 
for use in drug test kits.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objectives may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: Federal Register Representative, 
Office of Chief Counsel (CCD) and must be filed no later than February 
2, 2004.

    Dated: November 14, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 03-29961 Filed 12-1-03; 8:45 am]
BILLING CODE 4410-09-M